Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DL-Laudanosine (Laudanosine) 是 Atracurium 和 Cisatracurium 的代谢物,它能够透过血脑屏障,引起兴奋和癫痫。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 179 | 现货 | ||
5 mg | ¥ 385 | 现货 | ||
10 mg | ¥ 552 | 现货 | ||
25 mg | ¥ 889 | 现货 | ||
50 mg | ¥ 1,330 | 现货 | ||
100 mg | ¥ 1,980 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 341 | 现货 |
产品描述 | DL-Laudanosine (Laudanosine) is a recognized metabolite of atracurium and cisatracurium. |
体内活性 | laudanosine, a metabolite of atracurium and a central nervous system stimulant, might increase the minimum alveolar concentration (MAC) of halothane.?These estimates were used to determine the rates of infusion that would produce steady state plasma concentrations of laudanosine of approximately 200, 400, and 800 ng .?ml-1.?Subsequent infusion of laudanosine in eight rabbits produced mean (+/- SD) steady state plasma concentrations of laudanosine of 234 +/- 56, 457 +/- 66, and 873 +/- 105 ng .?ml-1.?The control value for MAC of halothane was 1.08 +/- 0.28%.?At the lowest steady state plasma laudanosine concentration, MAC did not significantly differ from control (MAC = 1.15 +/- 0.23%, P less than 0.1).?However, at 457 and 873 ng .?ml-1, laudanosine significantly increased the MAC of halothane by 23% and 30%, respectively.?Infusion with saline in two additional rabbits did not affect MAC. Therefore, at the plasma concentrations of laudanosine found in humans after administration of atracurium, laudanosine increased the MAC of halothane in rabbits[1]. |
别名 | Laudanosine, DL-劳丹素 |
分子量 | 357.44 |
分子式 | C21H27NO4 |
CAS No. | 1699-51-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 11 mg/mL (30.77 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.7977 mL | 13.9884 mL | 27.9767 mL | 69.9418 mL |
5 mM | 0.5595 mL | 2.7977 mL | 5.5953 mL | 13.9884 mL | |
10 mM | 0.2798 mL | 1.3988 mL | 2.7977 mL | 6.9942 mL | |
20 mM | 0.1399 mL | 0.6994 mL | 1.3988 mL | 3.4971 mL |
中药材名称 | 中药材拉丁名 | 性 | 味 | 归经 |
粗果唐松草 | Thalictrum aquilegifolium L.Var, sibiricum Reg.et Tiling | 寒 | 苦 | 心, 肺, 胃 |
罂粟 | Papaver somniferum L. | 平 | 甘 | 脾, 胃, 大肠 |
方剂名称 | 处方组成 | 剂型 | 处方来源 |
人参散208 | 罂粟,白扁豆,藿香,甘草,人参 | 散剂 | 《产宝诸方》。 |
香藤散 | 香藤,甘草,陈皮,羌活,厚朴,当归,罂粟 | 散剂 | 《鸡峰》卷十四。 |
御米饮子 | 当归,干姜,黄柏,枳壳,罂粟,甘草,罂粟壳 | 散剂 | 《杨氏家藏方》卷七。 |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
DL-Laudanosine 1699-51-0 Metabolism Others Drug Metabolite DLLaudanosine DL Laudanosine Inhibitor Laudanosine inhibit DL-劳丹素 inhibitor